Abstract: There is overwhelming evidence that the 4-dose vaccine schedule as part of postexposure prophylaxis to prevent human rabies for previously unvaccinated persons, as recommended by the Advisory Committee on Immunization Practices, United States in 2009, is safe and effective. When used appropriately with timely wound care and administration of human rabies immune globulin, the administration of 4 doses of vaccine on days 0, 3, 7, and 14 is likely to induce an adequate,long-lasting antibody response that is able to neutralize rabies virus and prevent disease in exposed patients. There has been no change in the recommended regimen for pre-exposure prophylaxis and for postexposure prophylaxis of previously vaccinated persons or for immunosuppressed patients.
TARGET AUDIENCE
This article is intended for physicians, nurse practitioners, and other medical providers who care for patients with animal bites and wounds who may need postexposure prophylaxis (PEP) to prevent human rabies.
LEARNING OBJECTIVES
After completion of this article, the reader should be able to: 1. Analyze the rationale for the change by Advisory Committee on Immunization Practices (ACIP) in its recommendation to reduce the number of vaccine doses from 5 to 4 as part of PEP to prevent human rabies. 2. Administer the recommended PEP to previously vaccinated persons and to immunosuppressed patients at risk of rabies.
Rabies is a zoonotic disease caused by RNA viruses in the family Rhabdoviridae and genus Lyssavirus. The virus is shed in the rabid animal's saliva and is transmitted through a bite into human tissues. Whereas in some subjects, the virus is cleared spontaneously, in others, it enters a nerve ending, and then spreads to the central nervous system by passive retrograde axonal transport and transsynaptic transmission. 1 After an incubation period of 5 days to a few months, rarely extending to more than 1 year, rabies virus thus causes an acute progressive encephalomyelitis, which is almost universally fatal. 2 With the elimination of endemic transmission among dogs in the United States, other animal control efforts, well-organized public health and surveillance system, and the availability of reliable human rabies immune globulin (HRIG) and vaccines, rabies has become rare, 1 to 2 cases being reported annually since the 1960s. 2 Rabies virus is still endemic among animals in the wild and among bats in the United States, leading to continuing risk of transmission to humans. Domestic animals, such as cats and dogs, can sometimes get rabies from contact with wild animals and thus pose risk to humans coming in contact with them. Rabies can be prevented by avoiding exposure to the virus and, in case of exposure, by rapid institution of PEP. The rabies virus seems to become inaccessible to immune surveillance once it enters a neuron. Hence, the aim of rabies prophylaxis is to kill or neutralize the virus by chemical or immunological means at the site of inoculation before it enters neurons. 1 No antiYrabies virus drug has been developed to date. The rabies PEP thus includes urgent wound care and administration of HRIG and rabies vaccine. A recent study estimated 23,000 cases of potential rabies exposure in the United States per year warranting PEP. 3 In the United States, a 5-dose PEP vaccine regimen (on days 0, 3, 7, 14, and 28), incorporating human diploid cell vaccine or purified chick embryo cell vaccine, given by intramuscular (IM) route was adopted during the 1980s. 4 The latest ACIP human rabies PEP guidelines incorporating a 5-dose vaccine schedule were published in 2008. 5 The same year, the ACIP formed a workgroup to review rabies vaccine regimen options in the United States. This article will explain the rationale for the change by the Advisory Committee on Immunization Practices to reduce the number of vaccine doses from 5 to 4 to prevent human rabies, and will provide information on administering the recommended postexposure prophylaxis to various groups of patients.
EVIDENCE FOR THE EFFICACY OF 4-DOSE RABIES VACCINE SERIES
The ACIP Rabies Workgroup recommended adopting a 4-dose vaccine series (on days 0, 3, 7, and 14), replacing the previously recommended 5-dose regimen for rabies PEP in previously unvaccinated persons. 2 This recommendation was based on a detailed review of data from all available sources regarding rabies virus pathogenesis, experimental animal models, human immunogenicity studies, effectiveness of rabies PEP in humans, documented failures of prophylaxis in humans, and vaccine safety. Randomized controlled trials comparing different vaccine schedules have not been conducted because of the severity of the disease. The review showed strong efficacy of PEP in various animal models without any effect of the number of vaccine doses used. 2 In human studies, rabies virusYneutralizing antibodies (surrogate marker for an adequate immune response to vaccination) are detectable by 7 to 10 days after initiation of vaccination and peak by 14 to 28 days, without any additive value of a fifth dose of vaccine administered on day 28. 2 The so-called Zagreb regimen of 2-1-1, which uses 4 doses of the vaccine in CME REVIEW ARTICLE total, 2 on day 0 on bilateral extremities, and subsequent doses on days 7 and 21, has been used successfully worldwide for many years and is recommended by the World Health Organization for PEP. 6 Besides, epidemiologic surveillance has failed to find any rabies cases among patients in the United States who received appropriate wound care, HRIG, and 4 doses of the vaccine instead of the recommended 5. The Working Group estimated that more than 1000 people in the United States receive PEP annually, comprising only 3 or 4 doses, yet with no resulting case of rabies, even though about a third of these cases may involve exposure to confirmed rabid animals. None of the 27 human rabies cases reported in the United States between 2000 and 2008 had received any PEP before the onset of illness. Since the advent of routine use of rabies PEP incorporating HRIG and cell-culture vaccines, no case of failure of this regimen has been reported in the United States or in Western Europe. 2 There have been very rare reports of failure of seemingly appropriate and prompt human PEP from developing countries, but no such case has ever been attributed to the lack of receipt of the fifth vaccine dose on day 28. 7, 8 Adequate PEP should also lead to sustained immunologic memory. Again, various studies have shown similar and persisting levels of rabies virusYneutralizing antibodies up to 14 to 20 years after the primary vaccination series independent of the number of doses of the vaccine. 2 The workgroup published a detailed review outlining the evidence in favor of switching to a 4-dose rabies vaccine schedule. 2 The ACIP accepted this recommendation in June 2009. This was followed by the publication of an updated guideline incorporating a 4-dose vaccine schedule as part of PEP to prevent human rabies in 2010. 9 The World Health Organization and the American Academy of Pediatrics have since endorsed these recommendations. 6, 10 A recent study in Puerto Rico among patients who had discontinued rabies PEP before completing a schedule of 5 vaccine doses showed that all PEP recipients who had received 3 to 4 vaccine doses exhibited seroconversion by the ACIP standard (the serum sample should completely neutralize challenge rabies virus at least at a 1:5 serum dilution by the rapid fluorescent focus inhibition test). 9, 11 The median interval between the last vaccine dose and serum collection was about 5 months, which suggests lack of a significant decay in antibody titer in the absence of a fourth or fifth vaccine dose. These findings further affirm that a PEP regimen composed of 4 vaccine doses is likely to lead to an effective immunological response against rabies. 11 
INDICATIONS FOR RABIES PEP
The prevalence of rabies in different animals varies from 25% in a skunk to 15% in a bat, 1% in a cat, and 0.1% in a dog. 12 Estimated values for rabies mortality following different exposures to proven rabid animals include 5% for superficial bite to the hand, 0.1% for contact with rabid saliva on a recent wound, and 0.0% for contact with rabid saliva on a wound older than 24 hours. 12 A panel of experienced public health experts estimated the median risk of rabies transmission after bite exposures by skunk, bat, cat, and dog (where the animal escaped and was not available for testing, and the wound was not washed at the time of injury) at 0.05, 0.001, 0.001, and 0.00001, respectively. All participants recommended rabies PEP in these scenarios. A nonbite exposure such as hand licking by a dog, cat, or human with rabies is likely to lead to a risk of less than 0.000001, and rabies PEP is not recommended in this scenario. 12 Nonbite exposures, such as contamination of open wounds or of mucous membranes with saliva, and abrasions very rarely cause rabies. 13 Other indirect contact such as petting or handling an animal; contact with blood, urine, feces; or contact of saliva with intact skin do not constitute exposures. 13 Information about all such cases along with animal's location and owner information should be provided to local department of public health. Discuss cases where the animal is unavailable for observation with the local public health department. Postexposure prophylaxis is likely to be recommended in such situations. & Exposure to bats: rabies PEP for persons exposed to bats should be limited to cases where a sleeping person, incapacitated person, or very young child has been in a room with a bat that is not available for testing, or if there is evidence of an obvious bite by the bat. If the bat is available for testing, provision of PEP should be based on test results. & Bites from squirrels, hamsters, guinea pigs, gerbils, chipmunks, rats, mice, other small rodents, and rabbits almost never require rabies PEP. Consult with local public health staff in case of concern. 13 
REVISED RABIES PEP RECOMMENDATIONS FOR UNVACCINATED PERSONS
In unvaccinated persons, a bite or nonbite exposure to rabies should be followed by immediate wound care and administration of HRIG as well as vaccine (Table 1) . 9 The PEP regimen remains the same irrespective of the patient's age and the time interval between exposure and its initiation. The regimen should ideally begin as soon as possible after exposure. The date of the first dose of the vaccine is considered day 0. Subsequent doses should be given 3, 7, and 14 days after the first dose. The vaccine dose is the same irrespective of patient's age. The vaccine should be administered IM in the deltoid area of the arm to adults and children 2 years or older. Anterolateral aspect of the thigh is recommended for younger children. 6, 9 The HRIG recommendations remain the same as before. It should 
PEP RECOMMENDATIONS FOR IMMUNOSUPPRESSED PERSONS
The recommendations for this group have not changed. All rabies vaccines are inactivated cell-culture vaccines that can be administered safely to immunosuppressed patients. Human rabies immune globulin is also safe for such patients. Because of the potential suppression of immune response, a 5-dose vaccine seriesVon days 0, 3, 7, 14, and 28Vis recommended. Immunosuppressive medications should be withheld during PEP unless essential. Serum samples should be tested for neutralizing antibody 1 to 2 weeks after completing the vaccine series to ensure an acceptable response. In the absence of this response, assess the need for an additional dose of the vaccine and consult appropriate public health officials for further individualized advice. 6, 9 This article has provided the rationale for the change by the Advisory Committee on Immunization Practices to reduce the number of vaccine doses from 5 to 4 to prevent human rabies, and has discussed administration of the recommended postexposure prophylaxis to various groups of patients.
